Eli Lilly Expands Global Reach with Mounjaro

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, and Mexico by 2026, targeting 900 million potential patients. Despite remarkable demand, supply constraints have delayed entering these emerging markets while awaiting the scaling up of production capabilities.

Eli Lilly aims to expand its global footprint by introducing its blockbuster drug, Mounjaro, to major markets such as China, India, Brazil, and Mexico by 2026, according to Chief Financial Officer Lucas Montarce.

The expansion targets a significant patient pool of 900 million people who could benefit from Mounjaro's diabetes and weight-loss capabilities. However, due to extraordinary global demand and supply issues, Lilly and its competitor, Novo Nordisk, have postponed pipeline expansions.

As it stands, Mounjaro, known as tirzepatide, is available in the UK and Europe. Approved last year by Chinese regulators, it is marketed for obesity treatment in the U.S under the name Zepbound. CEO David Ricks anticipates launching Mounjaro in India as soon as next year.

(With inputs from agencies.)